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 Drosophila-X Virus (DXV) is the prototype virus of the Entomobirnavirus 
genera in the family Birnaviridae; its genome consists of two double-stranded RNA 
segments.  DXV has two open reading frames on segment A, one encoding a 
polyprotein and the other capable of encoding a putative 27-kDa non structural 
protein (DXV-NS). 
 This project investigated the existence of DXV-NS since this putative protein 
is unique to Birnaviridae.  Research into the nature of DXV-NS was furthered by the 
development of a number of tools: recombinant baculovirus and a stable Drosophila 
cell line expressing DXV-NS; an antibody against NS; a reporter construct to test a 
potential -1 frameshift signal.  Though in the course of this research much was 
learned about DXV-NS, the greater question as to whether this open reading frame is 
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Introduction and Background 
 
1.1  Introduction 
 
 Drosophila-X Virus (DXV) is a member of the family Birnaviridae, viruses 
with genomes consisting of two double-stranded RNA segments (dsRNA).  DXV has 
two open reading frames on segment A, one encoding a polyprotein and the other 
capable of encoding a putative 27-kDa non structural protein (DXV-NS). 
 Research into DXV offers insight into the Birnaviruses and offers some 
advantages over other members of the family.  The natural host of DXV, Drosophila 
melanogaster, is a model organism with a fully sequenced genome and an abundance 
of resources and tools already tailor made for use in this system.  Drosophila are 
simpler and less expensive to grow and maintain than fish or fowl, the natural hosts of 
the other prototype viruses in this family.  There are well-established Drosophila cell 
lines which are easy to maintain and can support DXV infections.  Finally, DXV is 
the only Birnavirus with an internal overlapping open reading frame (ORF) on 
segment A with the potential to encode a non-structural protein (DXV-NS), a unique 
feature which makes this virus an interesting target for investigation. 
 The research in support of this thesis investigated the existence of DXV-NS.  
Though we can not yet give a definitive answer as to whether DXV expresses this 
protein, this thesis will report some new information on DXV-NS as well as present a 




1.2  DXV Discovery 
 
Drosophila-X Virus (DXV) was first isolated in 1978 as a contaminant in 
experiments studying the insect rhabdovirus Sigma.  While it is common practice to 
use CO2 to anesthetize Drosophila melanogaster with little to no lasting side effects, 
Sigma virus produces an anoxia sensitivity phenotype in infected flies distinguished 
by death within approximately 15 minutes of exposure.  In one control run of 
Drosophila uninfected with Sigma, the anoxia sensitivity phenotype was observed.  
Subsequent electron microscopy of tissue collected from the “uninfected” flies 
revealed unknown icosahedral unenveloped virus particles (Figure 1) but no 
rhabdoviruses indicating the presence of a second unrelated virus which exhibited a 
similar phenotype.  The unknown virus was isolated from homogenized flies, 
characterized, and designated Drosophila-X Virus (Teninges et al., 1979).   
 
 
1.3  DXV Taxonomy 
 
The Birnaviridae family of viruses is grouped by host into three genera–
Aquabirnavirus, Avibirnavirus, and Entomobirnavirus–with each genus represented  
by a prototypical virus.  Drosophila-X Virus stands as the prototype and sole known 




















Figure 1.  Electron micrograph of Drosophila-X Virus.  The icosahedral capsids are 
59 nm in diameter.  Light colored particles are complete virions.  Dark particles are 
defective, empty capsids lacking genomic material.  (Zambon and Edwards, 
unpublished). 
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remains the least studied.  Infectious pancreatic necrosis virus (IPNV) and infectious 
bursal disease virus (IBDV) are two well characterized members of Aqua- and 
Avibirnavirus respectively and account for much of the current knowledge about the 
structure and function of birnaviruses.  Research into both of these viruses holds a 
great deal of value to agriculture since each can lead to death of economically 
valuable hosts.  In aquaculture operations, IPNV can kill immature salmanoid fishes 
such as salmon and trout by destroying the pancreas (Shivappa et al., 2004; Wolf, 
1988).  IBDV is likewise a threat to poultry farming, causing death to young chickens 
by necrosis of the bursa of Fabricius, a lymphoid organ and component of the avian 
immune system (Becht, 1980; Yao and Vakharia, 2001). 
The Birnaviridae family was first proposed in 1979 based on an analysis of 
five novel related viruses–including DXV, IPNV and IBDV–which did not fit any 
known taxonomical classification (Dobos et al., 1979).  The family name and 
characteristics were later codified and accepted by the International Committee on 
Taxonomy of Viruses in 1986 (Dobos, 1995; Dobos et al., 1995).  The family is 
characterized by unenveloped viruses with a small single layer icosahedral 
nucleocapsid approximately 60 nm in diameter.  The genome is bi-segmented and 
contains double-stranded RNA (Dobos et al., 1979).  The genomes of all members 
exhibit a strong degree of conservation with regards to structure (Figure 2).  At the 
most basic level of comparison, each encodes a three member polyprotein on the A 
segment and an RNA-dependent RNA polymerase (RdRP) designated Viral Protein 1  
(VP1) on segment B.  The polyprotein from the primary reading frame of segment A 

















Figure 2.  Comparison of the genome structures of the three prototypical 
Birnaviruses: Drosophila-X Virus (DXV), Infectious Pancreatic Necrosis Virus 
(IPNV), and Infectious Bursal Disease Virus (IBDV).  Note the smaller overlapping 
reading frame in DXV which encodes the putative non-structural 27-kDa protein 
(Chung et al., 1996). 
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are capsid proteins and VP4 is a protease.  This pattern of protein expression was 
confirmed in DXV in 1984 (Nagy and Dobos, 1984a; Nagy and Dobos, 1984b). 
 
 
1.4  DXV Physical Properties and Structure 
 
Drosophila-X Virus is structurally typical of other members of the 
Birnaviridae family.   It consists of a 59 nm icosahedral nucleocapsid and a bi-
segmented double-stranded RNA genome.  The genome segments A and B have 
molecular weights of 2.6 x 106 and 2.5 x 106, respectively.  The virions have a density 
of 1.345 g/mL in a cesium chloride gradient.  Defective particles, empty capsids 
lacking a genome, have a lower density than the complete virions, approximately 1.3 
g/mL (Teninges, 1979; Teninges et al., 1979).    
DXV segment B is the smaller of the two at 3243 bp.  The RNA dependent 
RNA polymerase VP1 encoded by segment B is 112-kDa.  It can be found in both a 
free and genome-bound form in the virion (Revet and Delain, 1982; Nagy and Dobos, 
1984a; Nagy and Dobos, 1984b; Shwed et al., 2002).   
 Segment A of DXV was first sequenced in 1996 and found to be 3360 bp 
long.  The segment contains two significant overlapping open reading frames, one 
3096 nucleotides long starting at position 108 and a smaller 711 nt ORF in the -1 
frame beginning at position 1922 (Chung et al., 1996) (Figure 3).  The primary open 
reading frame encodes a 114-kDa polyprotein, consistent with other members of 
Birnaviridae. (Chung et al., 1996; Dobos et al., 1979; Duncan et al., 1987).  This  
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DNA: GGAAAATAAATGGCGGCCGACAAGGCCGACCGATTTATCAGGGTAGAGGGA 51 
  0:   E  N  K  W  R  P  T  R  P  T  D  L  S  G  *  R  D  
 -1:  G  K  *  M  A  A  D  K  A  D  R  F  I  R  V  E  G   
 
DNA: CCTTACAAACCAGTGAAACCTCCAAAATTTTTTAAACTGATACAATACATG 102 
  0:   L  T  N  Q  *  N  L  Q  N  F  L  N  *  Y  N  T  *  
 -1:  P  Y  K  P  V  K  P  P  K  F  F  K  L  I  Q  Y  M   
 
DNA: AATGACAATGAATACGACAAACGAATACTTGAAAACTCTTTTAAACCCAGC 153 
  0:   M  T  M  N  T  T  N  E  Y  L  K  T  L  L  N  P  A  
 -1:  N  D  N  E  Y  D  K  R  I  L  E  N  S  F  K  P  S   
 
DNA: ACAATTTATCTCAGACATTCCTGATGATATAATGATCCGACACGTAAACAG 204 
  0:   Q  F  I  S  D  I  P  D  D  I  M  I  R  H  V  N  S  
 -1:  T  I  Y  L  R  H  S  *  *  Y  N  D  P  T  R  K  Q   
 
DNA: CGCCCAGACCATCACCTACAACTTGAAGTCAGGGGCCTCTGGCACCGGCCT 255 
  0:   A  Q  T  I  T  Y  N  L  K  S  G  A  S  G  T  G  L  
 -1:  R  P  D  H  H  L  Q  L  E  V  R  G  L  W  H  R  P   
 
DNA: GATCGTGGTCTATCCAAACACCCCGTCGAGTATTAGCGGCTTCCATTACAT 206 
  0:   I  V  V  Y  P  N  T  P  S  S  I  S  G  F  H  Y  I  
 -1:  D  R  G  L  S  K  H  P  V  E  Y  *  R  L  P  L  H   
 
DNA: ATGGGATTCCGCTACCTCGAATTGGGTGTTTGATCAGTACATCTACACAGC 357 
  0:   W  D  S  A  T  S  N  W  V  F  D  Q  Y  I  Y  T  A  
 -1:  M  G  F  R  Y  L  E  L  G  V  *  S  V  H  L  H  S   
 
DNA: TCAGGAGTTGAAGGACTCATATGACTATGGCAGACTGATTTCAGGCTCGCT 408 
  0:   Q  E  L  K  D  S  Y  D  Y  G  R  L  I  S  G  S  L  
 -1:  S  G  V  E  G  L  I  *  L  W  Q  T  D  F  R  L  A   
 
DNA: AAGCATTAAGTCCAGCACCTTACCTGCGGGTGTTTATGCACTGAATGGCAC 459 
  0:   S  I  K  S  S  T  L  P  A  G  V  Y  A  L  N  G  T  
 -1:  K  H  *  V  Q  H  L  T  C  G  C  L  C  T  E  W  H   
 
DNA: ATTCAATGCAGTCTGGTTCCAAGGGACCTTGAGTGAAGTGTCTGACTACTC 510 
  0:   F  N  A  V  W  F  Q  G  T  L  S  E  V  S  D  Y  S  
 -1:  I  Q  C  S  L  V  P  R  D  L  E  *  S  V  *  L  L   
 
DNA: TTACGATAGGATCCTGTCAATAACATCCAATCCTCTGGATAAGGTTGGAAA 561 
  0:   Y  D  R  I  L  S  I  T  S  N  P  L  D  K  V  G  N  
 -1:  L  R  *  D  P  V  N  N  I  Q  S  S  G  *  G  W  K   
 
DNA: TGTGTTGGTTGGAGACGGCATAGAGGTTCTAAGCCTGCCGCAGGGGTTCAA 612 
  0:   V  L  V  G  D  G  I  E  V  L  S  L  P  Q  G  F  N  
 -1:  C  V  G  W  R  R  H  R  G  S  K  P  A  A  G  V  Q   
 
DNA: CAACCCCTACGTTAGGCTGGGTGACAAGTCACCGTCCACTCTATCCTCTCC 663 
  0:   N  P  Y  V  R  L  G  D  K  S  P  S  T  L  S  S  P  





DNA: AACCCACATAACCAACACTTCCCAGAACTTGGCTACGGGAGGTGCATACAT 714 
  0:   T  H  I  T  N  T  S  Q  N  L  A  T  G  G  A  Y  M  
 -1:  N  P  H  N  Q  H  F  P  E  L  G  Y  G  R  C  I  H   
 
DNA: GATCCCAGTAACCACAGTTCCTGGGCAAGGATTCCATAACAAGGAATTCAG 765 
  0:   I  P  V  T  T  V  P  G  Q  G  F  H  N  K  E  F  S  
 -1:  D  P  S  N  H  S  S  W  A  R  I  P  *  Q  G  I  Q   
 
DNA: CATTAATGTGGACTCCGTAGGGCCAGTTGACATCTTGTGGTCTGGTCAAAT 816 
  0:   I  N  V  D  S  V  G  P  V  D  I  L  W  S  G  Q  M  
 -1:  H  *  C  G  L  R  R  A  S  *  H  L  V  V  W  S  N   
 
DNA: GACTATGCAGGACGAATGGACTGTAACTGCAAATTATCAACCATTGAACAT 867 
  0:   T  M  Q  D  E  W  T  V  T  A  N  Y  Q  P  L  N  I  
 -1:  D  Y  A  G  R  M  D  C  N  C  K  L  S  T  I  E  H   
 
DNA: CTCTGGCACGCTAATTGCAAACAGTCAGCGAACCCTAACATGGTCCAACAC 918 
  0:   S  G  T  L  I  A  N  S  Q  R  T  L  T  W  S  N  T  
 -1:  L  W  H  A  N  C  K  Q  S  A  N  P  N  M  V  Q  H   
 
DNA: TGGTGTATCCAATGGCAGCCACTACATGAACATGAACAACCTTAATGTCTC 969 
  0:   G  V  S  N  G  S  H  Y  M  N  M  N  N  L  N  V  S  
 -1:  W  C  I  Q  W  Q  P  L  H  E  H  E  Q  P  *  C  L   
 
DNA: CCTTTTCCATGAGAATCCACCACCTGAACCCGTTGCCGCCATAAAAATAAA 1020 
  0:   L  F  H  E  N  P  P  P  E  P  V  A  A  I  K  I  N  
 -1:  P  F  P  *  E  S  T  T  *  T  R  C  R  H  K  N  K   
 
DNA: CATCAATTATGGAAACAACACCAATGGTGACAGCTCGTTCAGTGTGGACTC 1071 
  0:   I  N  Y  G  N  N  T  N  G  D  S  S  F  S  V  D  S  
 -1:  H  Q  L  W  K  Q  H  Q  W  *  Q  L  V  Q  C  G  L   
 
DNA: ATCATTTACCATCAATGTCATTGGGGGCGCCACCATTGGCGTCAACTCTCC 1122 
  0:   S  F  T  I  N  V  I  G  G  A  T  I  G  V  N  S  P  
 -1:  I  I  Y  H  Q  C  H  W  G  R  H  H  W  R  Q  L  S   
 
DNA: AACAGTCGGTGTTGGTTACCAAGGAGTAGCTGAGGGCACCGCCATTACAAT 1173 
  0:   T  V  G  V  G  Y  Q  G  V  A  E  G  T  A  I  T  I  
 -1:  N  S  R  C  W  L  P  R  S  S  *  G  H  R  H  Y  N   
 
DNA: TAGCGGTATCAACAACTATGAGCTGGTACCCAATCCGGACTTGCAAAAGAA 1224 
  0:   S  G  I  N  N  Y  E  L  V  P  N  P  D  L  Q  K  N  
 -1:  *  R  Y  Q  Q  L  *  A  G  T  Q  S  G  L  A  K  E   
 
DNA: CCTGCCAATGACATATGGCACTTGTGATCCACATGATTTGACTTACATCAA 1275 
  0:   L  P  M  T  Y  G  T  C  D  P  H  D  L  T  Y  I  K  
 -1:  P  A  N  D  I  W  H  L  *  S  T  *  F  D  L  H  Q   
 
DNA: GTACATACTGTCAAACCGAGAACAGTTGGGACTTAGGTCAGTGATGACCTT 1326 
  0:   Y  I  L  S  N  R  E  Q  L  G  L  R  S  V  M  T  L  
 -1:  V  H  T  V  K  P  R  T  V  G  T  *  V  S  D  D  L   
 
DNA: GGCCGACTACAATAGGATGAAGATGTACATGCATGTACTGACGAACTATCA 1377 
  0:   A  D  Y  N  R  M  K  M  Y  M  H  V  L  T  N  Y  H  




DNA: TGTCGATGAGAGGGAAGCATCGAGCTTCGATTTCTGGCAACTACTGAAACA 1428 
  0:   V  D  E  R  E  A  S  S  F  D  F  W  Q  L  L  K  Q  
 -1:  C  R  *  E  G  S  I  E  L  R  F  L  A  T  T  E  T   
 
DNA: GATAAAAAATGTTGCCGTGCCCTTGGCAGCTACACTTGCCCCCCAGTTCGC 1479 
  0:   I  K  N  V  A  V  P  L  A  A  T  L  A  P  Q  F  A  
 -1:  D  K  K  C  C  R  A  L  G  S  Y  T  C  P  P  V  R   
 
DNA: ACCAATAATCGGTGCTGCCGATGGGTTAGCCAATGCAATATTGGGTGATAG 1530 
  0:   P  I  I  G  A  A  D  G  L  A  N  A  I  L  G  D  S  
 -1:  T  N  N  R  C  C  R  W  V  S  Q  C  N  I  G  *  *   
 
DNA: CGCCAGCGGAAGGCCTGTTGGCAATTCCGCTAGCGGTATGCCCATTTCAAT 1581 
  0:   A  S  G  R  P  V  G  N  S  A  S  G  M  P  I  S  M  
 -1:  R  Q  R  K  A  C  W  Q  F  R  *  R  Y  A  H  F  N   
 
DNA: GAGTAGGCGTCTTAGAAACGCTTACTCAGCTGACTCCCCCTTAGGTGAAGA 1632 
  0:   S  R  R  L  R  N  A  Y  S  A  D  S  P  L  G  E  E  
 -1:  E  *  A  S  *  K  R  L  L  S  *  L  P  L  R  *  R   
 
DNA: GCATTGGCTGCCAAACGAGAATGAGAACTTCAATAAATTTGACATCATCTA 1683 
  0:   H  W  L  P  N  E  N  E  N  F  N  K  F  D  I  I  Y  
 -1:  A  L  A  A  K  R  E  *  E  L  Q  *  I  *  H  H  L   
 
DNA: TGACGTATCACATTCATCCATGGCTTTATTTCCAGTCATAATGATGGAACA 1734 
  0:   D  V  S  H  S  S  M  A  L  F  P  V  I  M  M  E  H  
 -1:  *  R  I  T  F  I  H  G  F  I  S  S  H  N  D  G  T   
 
DNA: TGACAAAGTCATTCCATCCGACCCTGAGGAGCTGTATATTGCTGTATCACT 1785 
  0:   D  K  V  I  P  S  D  P  E  E  L  Y  I  A  V  S  L  
 -1:  *  Q  S  H  S  I  R  P  *  G  A  V  Y  C  C  I  T   
 
DNA: AACAGAATCCCTCAGGAAGCAAATACCGAACCTCAATGACATGCCATACTA 1836 
  0:   T  E  S  L  R  K  Q  I  P  N  L  N  D  M  P  Y  Y  
 -1:  N  R  I  P  Q  E  A  N  T  E  P  Q  *  H  A  I  L   
 
DNA: TGAGATGGGTGGCCATAGGGTGTACAACTCCGTTTCCTCAAACGTAAGATC 1887 
  0:   E  M  G  G  H  R  V  Y  N  S  V  S  S  N  V  R  S  
 -1:  *  D  G  W  P  *  G  V  Q  L  R  F  L  K  R  K  I   
 
DNA: TGGAAATTTTTTAAGAAGCGATTACATCCTCCTACCATGCTATCAATTATT 1938 
  0:   G  N  F  L  R  S  D  Y  I  L  L  P  C  Y  Q  L  L  
 -1:  W  K  F  F  K  K  R  L  H  P  P  T  M  L  S  I  I   
 
DNA: AGAAGGAAGACTCGCATCGTCGACATCACCAAACAAGGTAACGGGAACGTC 1989 
  0:   E  G  R  L  A  S  S  T  S  P  N  K  V  T  G  T  S  
 -1:  R  R  K  T  R  I  V  D  I  T  K  Q  G  N  G  N  V   
 
DNA: CCACCAGCTTGCCATTTATGCAGCAGACGACTTACTAAAGAGTGGAGTTTT 2040 
  0:   H  Q  L  A  I  Y  A  A  D  D  L  L  K  S  G  V  L  
 -1:  P  P  A  C  H  L  C  S  R  R  L  T  K  E  W  S  F   
 
DNA: GGGGAAGGCACCATTTGCAGCTTTCACAGGATCCGTTGTCGGGTCCAGTGT 2091 
  0:   G  K  A  P  F  A  A  F  T  G  S  V  V  G  S  S  V  




DNA: GGGAGAAGTTTTTGGCATCAACCTGAAACTCCAATTGACGGACTCTCTTGG 2142 
  0:   G  E  V  F  G  I  N  L  K  L  Q  L  T  D  S  L  G  
 -1:  G  R  S  F  W  H  Q  P  E  T  P  I  D  G  L  S  W   
 
DNA: GATTCCACTACTTGGGAACTCACCAGGATTAGTTCAAGTAAAGACCCTGAC 2193 
  0:   I  P  L  L  G  N  S  P  G  L  V  Q  V  K  T  L  T  
 -1:  D  S  T  T  W  E  L  T  R  I  S  S  S  K  D  P  D   
 
DNA: ATCTCTGGACAAAAAGATAAAAGATATGGGAGACGTAAAGAGAAGAACCCC 2244 
  0:   S  L  D  K  K  I  K  D  M  G  D  V  K  R  R  T  P  
 -1:  I  S  G  Q  K  D  K  R  Y  G  R  R  K  E  K  N  P   
 
DNA: AAAACAGACCCTCCCGCACTGGACAGCCGGGTCCGCGAGCATGAACCCATT 2295 
  0:   K  Q  T  L  P  H  W  T  A  G  S  A  S  M  N  P  F  
 -1:  K  T  D  P  P  A  L  D  S  R  V  R  E  H  E  P  I   
 
DNA: CATGAACACGAACCCATTCCTGGAAGAGTTGGACCAGCCGATACCAAGCAA 2346 
  0:   M  N  T  N  P  F  L  E  E  L  D  Q  P  I  P  S  N  
 -1:  H  E  H  E  P  I  P  G  R  V  G  P  A  D  T  K  Q   
 
DNA: CGCTGCAAAGCCAATCTCCGAGGAGACTCGGGATTTGTTTCTATCGGACGG 2397 
  0:   A  A  K  P  I  S  E  E  T  R  D  L  F  L  S  D  G  
 -1:  R  C  K  A  N  L  R  G  D  S  G  F  V  S  I  G  R   
 
DNA: TCAAACCATCCCAAGCTCTCAAGAGAAGATTGCCACAATACACGAGTACCT 2448 
  0:   Q  T  I  P  S  S  Q  E  K  I  A  T  I  H  E  Y  L  
 -1:  S  N  H  P  K  L  S  R  E  D  C  H  N  T  R  V  P   
 
DNA: CCTGGAACACAAGGAGTTAGAGGAGGCAATGTTCAGCTTGATAAGCCAAGG 2499 
  0:   L  E  H  K  E  L  E  E  A  M  F  S  L  I  S  Q  G  
 -1:  P  G  T  Q  G  V  R  G  G  N  V  Q  L  D  K  P  R   
 
DNA: GAGAGGCCGGTCTCTTATCAACATGGTAGTAAAAAGCGCTCTGAACATCGA 2550 
  0:   R  G  R  S  L  I  N  M  V  V  K  S  A  L  N  I  E  
 -1:  E  R  P  V  S  Y  Q  H  G  S  K  K  R  S  E  H  R   
 
DNA: AACCCAGTCTCGAGAAGTCACCGGCGAAAGAAGGCAAAGACTAGAACGAAA 2601 
  0:   T  Q  S  R  E  V  T  G  E  R  R  Q  R  L  E  R  K  
 -1:  N  P  V  S  R  S  H  R  R  K  K  A  K  T  R  T  K   
 
DNA: ACTTCGAAACTTGGAAAATCAAGGGATATATGTTGATGAGAGCAAAATAAT 2652 
  0:   L  R  N  L  E  N  Q  G  I  Y  V  D  E  S  K  I  M  
 -1:  T  S  K  L  G  K  S  R  D  I  C  *  *  E  Q  N  N   
 
DNA: GTCAAGAGGAAGAATATCGAAAGAAGACACGGAACTAGCAATGAGGATTGC 2703 
  0:   S  R  G  R  I  S  K  E  D  T  E  L  A  M  R  I  A  
 -1:  V  K  R  K  N  I  E  R  R  H  G  T  S  N  E  D  C   
 
DNA: TCGGAAGAACCAAAAGGATGCAAAGTTACGGAGAATCTATAGCAATAACGC 2754 
  0:   R  K  N  Q  K  D  A  K  L  R  R  I  Y  S  N  N  A  
 -1:  S  E  E  P  K  G  C  K  V  T  E  N  L  *  Q  *  R   
 
DNA: CTCGATCCAAGAGTCGTACACTGTGGATGACTTTGTATCCTATTGGATGGA 2805 
  0:   S  I  Q  E  S  Y  T  V  D  D  F  V  S  Y  W  M  E  




DNA: GCAGGAGTCATTGCCTACTGGCATACAAATCGCAATGTGGTTAAAGGGTGA 2856 
  0:   Q  E  S  L  P  T  G  I  Q  I  A  M  W  L  K  G  D  
 -1:  A  G  V  I  A  Y  W  H  T  N  R  N  V  V  K  G  *   
 
DNA: CGATTGGTCCCAGCCAATACCACCTCGTGTCCAAAGACGACACTATGACAG 2907 
  0:   D  W  S  Q  P  I  P  P  R  V  Q  R  R  H  Y  D  S  
 -1:  R  L  V  P  A  N  T  T  S  C  P  K  T  T  L  *  Q   
 
DNA: CTACATTATGATGCTTGGGCCGTCACCAACCCAAGAACAAGCCGATGCTGT 2958 
  0:   Y  I  M  M  L  G  P  S  P  T  Q  E  Q  A  D  A  V  
 -1:  L  H  Y  D  A  W  A  V  T  N  P  R  T  S  R  C  C   
 
DNA: TAAGGACCTTGTCGACGACATATACGACAGAAATCAAGGGAAGGGGCCATC 3009 
  0:   K  D  L  V  D  D  I  Y  D  R  N  Q  G  K  G  P  S  
 -1:  *  G  P  C  R  R  H  I  R  Q  K  S  R  E  G  A  I   
 
DNA: CCAGGAACAAGCTCGGGAATTAAGTCATGCTGTCCGCAGGCTTATTTCGCA 3060 
  0:   Q  E  Q  A  R  E  L  S  H  A  V  R  R  L  I  S  H  
 -1:  P  G  T  S  S  G  I  K  S  C  C  P  Q  A  Y  F  A   
 
DNA: CTCACTTGTCAACCAACCGGCAACTGCTCCTAGAGTCCCCCCACGCCGAAT 3111 
  0:   S  L  V  N  Q  P  A  T  A  P  R  V  P  P  R  R  I  
 -1:  L  T  C  Q  P  T  G  N  C  S  *  S  P  P  T  P  N   
 
DNA: TGTATCAGCTCAGACTGCTCAAACTGATCCCCCCGGAAGGAGGGCCGCACT 3162 
  0:   V  S  A  Q  T  A  Q  T  D  P  P  G  R  R  A  A  L  
 -1:  C  I  S  S  D  C  S  N  *  S  P  R  K  E  G  R  T   
 
DNA: TGACCGATTGCGAAGAGTGCGTGGAGAGGACAATGACATTGTATAAGTCCA 3213 
  0:   D  R  L  R  R  V  R  G  E  D  N  D  I  V  *  V  H  
 -1:  *  P  I  A  K  S  A  W  R  G  Q  *  H  C  I  S  P   
 
DNA: CCCATGAACTCATGACTCATGGGCCGTCAGAGAGAGGAGGGTGAGGAGAAT 3264 
  0:   P  *  T  H  D  S  W  A  V  R  E  R  R  V  R  R  I  
 -1:  P  M  N  S  *  L  M  G  R  Q  R  E  E  G  E  E  N   
 
DNA: TTTAGAGGGTAGTGCCAACTACACTAACAAACCACTAGACTATTGAAGTCG 3315 
  0:   L  E  G  S  A  N  Y  T  N  K  P  L  D  Y  *  S  R  
 -1:  F  R  G  *  C  Q  L  H  *  Q  T  T  R  L  L  K  S   
 
DNA: CCTGGTCTCATTAGCCAGGAAATCACGGTATCGAATCCGTGGTGGTTCCC  3365 
  0:   L  V  S  L  A  R  K  S  R  Y  R  I  R  G  G  S   
 -1:  P  G  L  I  S  Q  E  I  T  V  S  N  P  W  W  F   
 
Figure 3.  Sequence of Drosophila-X Virus segment A.  The sequence of our full-
length DXV segment A cDNA clone is given along with the translations of the 0 and 
-1 reading frames.  The zero frame encodes the polyprotein starting at nt 104 and NS 
is encoded in the -1 frame (bold) starting at nt 1924 and ending at 2635 (Chung et al., 
1996; Zambon, unpublished). 
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protein is arranged in the order NH2-preVP2-VP4-VP3-COOH (Nagy and Dobos, 
1984b).  Pulse-chase experiments revealed the sequence of processing events, initially 
self-cleavage by the protease VP4 (27-kDa) producing preVP2 (67-kDa) and VP3 
(34-kDa).  The precursor protein preVP2 undergoes further processing to pVP2 (49-
kDa) which matures into VP2 (45-kDa).  All of these proteins have been detected in 
the virion.  VP2 and VP3 are both known structural proteins, while pVP2 is 
detectable in capsids and therefore may also play a role in capsid formation (Nagy 
and Dobos, 1984a).  VP3 associates with the genome and is known as the inner 
capsid protein while VP2 does not appear to do so and is considered the outer capsid 
protein (Table 1). 
The smaller 711 bp ORF on segment A has the potential to encode a 27-kDa 
protein that has not been detected in virions.  This putative protein is called 




1.5  Properties of the DXV-NS Putative Protein 
 
 The sequence for DXV-NS codes for 237 residues.  A very high proportion 
(27%) of the amino acid residues comprising NS are basic including 31 arginines, 
which gives the projected protein a calculated pI value of 11 (Chung et al., 1996).  It  
has been theorized that the highly basic nature of NS could indicate a nucleic acid 







Name Size (kDa) Function
Polyprotein 114 precursor to VP2-4
preVP2 67 precursor to pVP2
pVP2 49 precursor to VP2; capsid?
VP2 45 outer capsid
VP3 34 inner capsid
VP4 27 protease
NS 27 unknown





Table 1.  Known and projected Drosophila-X Virus proteins.  The polyprotein is 
cleaved into preVP2, VP4, and VP3.  The precursor preVP2 gives rise to pVP2 which 
is in turn processed to pVP2. 
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bipartite nuclear targeting sequence characterized by two adjacent basic residues, a 
ten residue spacer, and five basic residues (Figure 4).    
 Both IPNV and IBDV also encode small non-structural arginine-rich peptides 
in a separate overlapping reading frame on segment A (Figure 2).  These peptides are 
similarly low in methionine, each containing two residues, while DXV-NS contains 
only a single one.  However in these related viruses, the peptide is located near the 5’ 
end, not overlapping the junction between VP4 and VP3 as is the case in DXV 
(Chung et al., 1996; Magyar and Dobos, 1994; Mundt et al., 1995).   
The function of these small proteins–17-kDa in IPNV and 16.6-kDa in IBDV–
is not entirely known, but there is evidence that both may play some role in the 
apoptosis mechanism of infected cells.  In IBDV, the virus is known to cause 
apoptosis in chicken embryo fibroblast (CEF) cells (Jungmann, et al., 2001) and a 
mutant strain lacking the 17-kDa NS protein was demonstrated to have reduced 
apoptotic effects (Yao et al., 1998).  In vitro expression of the IBDV-NS protein from 
a plasmid containing the gene was shown to induce apoptosis in CEF cells (Yao and 
Vakharia, 2001).   
 IPNV infection has a similar pro-apoptotic effect in Chinook salmon embryo 
cells (CHSE-214) (Hong et al., 1998; Hong et al., 1999) although it has been reported 
that in this virus the 17-kDa protein (known as VP5) shares some sequence features 
with anti-apoptotic factors (Hong et al., 2002).  Mutant IPNV strains that eliminate 
VP5 expression demonstrate that the protein is not essential to replication or virulence 
(Song, 2003).   







MLSIIRRKTRIVDITKQGNGNVPPACHLCSRRLTKEWSFG  1-40 
EGTICSFHRIRCRVQCGRSFWHQPETPIDGLSWDSTTWEL  41-80 
TRISSSKDPDISGQKDKRYGRRKEKNPKTDPPALDSRVRE  81-120 
HEPIHEHEPIPGRVGPADTKQRCKANLRGDSGFVSIGRSN  121-160 
HPKLSREDCHNTRVPPGTQGVRGGNVQLDKPRERPVSYQH  161-200  
GSKKRSEHRNPVSRSHRRKKAKTRTKTSKLGKSRDIC     201-237 
 
 
Figure 4.  DXV-NS putative protein sequence and bipartite nuclear targeting 
sequence (residues 204 to 220).  The motif is defined by two basic residues (bold), a 
spacer sequence of ten amino acids (italics), and at least three basic residues out of 
the next five (bold). 
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in segment A capable of encoding a second putative non-structural protein.  The 
putative 25-kDa protein (IPNV-Sp-NS) is highly basic and contains a nuclear 
targeting signal, just like DXV-NS.   The two putative proteins share a 12.7% identity 
and a 44% similarity.  (Shivappa et al., 2004; Song, 2003).  However, the protein has 
not been detected in vivo and a mutant IPNV virus eliminating the reading frame for 
the 25-kDa protein does not appear to have an effect on the virus replication in CHES 
cells.  The existence and function of IPNV-Sp-NS are still unknown (Song, 2003). 
A comparison of the amino acid sequences for IPNV-VP5, IBDV 17-kDa, and 
DXV-NS show a biochemical similarity.  The three sequences exhibit a 23% overall 
residue homology which rises to 44% if you consider similarity between any two of 
the three viruses (Chung et al., 1996).  This high degree of similarity is striking since 
the DXV-NS ORF is found in a different area of segment A from the basic IPNV and 
IBDV proteins.  The significance of the similarities between the small basic proteins, 
DXV-NS, and the 25-kDa putative protein of IPNV-Sp is unknown.  Based on the 
importance of IPNV-VP5 and IBDV 17-kDa in their respective viruses, DXV-NS 
could be a factor in DXV virulence and host interaction. 
 
 
1.6  Putative Mechanisms for NS Expression 
 
 The DXV-NS ORF is located in the middle of segment A, its start sequence 
overlapping the coding region for the polyprotein.  If the NS protein is made by 
Drosophila-X Virus, the mechanism for translation is unknown.  The polyprotein 
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ORF and the start codon of the DXV-NS ORF are both preceded by an identical motif 
consisting of sequences at the -34 and -13 positions.  The motif 5’-AAATTTTTTAA-
3’is located 34 nt upstream from both ORFs and a 5’-TACAT-3’ sequence is found at 
the -13 position.  Other groups have speculated that these identical motifs could 
represent a promoter sequence (Chung et al., 1996).  Perhaps there is an unknown 
internal ribosome entry site (IRES).  However based on analysis of the sequence 
around the start of the NS ORF, we investigated the alternate possibility that NS 
could be expressed through -1 frameshifting from the polyprotein.  A fusion with a 
portion of the polyprotein would result in a much larger band, and could explain why 
we do not find NS at 27-kDa in DXV infections. 
 Programmed -1 ribosomal frameshifting (-1 PRF) is a known mechanism for 
expression in some viruses, the prototype being gag-pol fusion proteins found in 
Saccharomyces cerevisiae virus L-A and many retroviruses (Brierley et al., 1989; 
Dinman et al., 1991; Plant et al., 2003).  A -1 PRF signal consists of three 
components: a slippery site, spacer region, and pseudoknot.  Slippery sites are 
heptameric signals in RNA that conform to the motif X XXY YYZ, where X=A,U,G; 
Y=A,U; Z=A,U,C  (Brierley et al., 1989; Brierley et al., 1992; Dinman et al., 1991; 
Plant et al., 2003).  They are separated from a downstream pseudoknot-forming stem-
loop structure by a short spacer about 10 nucleotides long.  A pseudoknot is a 
structure formed by base pairing of a stem loop with downstream bases  (Brierley et 
al., 1989, Plant et al., 2003) 
During translation, a ribosome reading in the zero frame comes up against the 
pseudoknot while the slippery site is in the ribosomal P and A tRNA sites.  The 
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ribosome pauses while the secondary structure of the pseudoknot is resolved, 
allowing simultaneous slippage of both tRNAs in the -1 direction.  When the 
ribosome resumes translation, it continues reading in the -1 frame.  The frameshifting 
efficiency allows the virus to regulate the rate of expression of the downstream 
protein (Brierley et al., 1989; Dinman et al., 1991; Plant et al., 2003).   
At the time that DXV segment A was sequenced, Chung reported that they did 
not find a slippery site (Chung et al., 1996).  However, we will report new results 
utilizing the most recent search algorithms which indicate a slippery site may exist, 
opening the possibility that -1 frameshifting may be used to express DXV-NS. 
 
 
1.7  Infection in Flies 
 
 Drosophila-X Virus exhibits an anoxia sensitivity phenotype in Drosophila 
melanogaster, its only known host.  Drosophila become immobilized under anoxic 
conditions, usually induced in the laboratory by exposure to CO2.  The flies can 
normally tolerate long periods of anoxia without suffering any pronounced effects 
once oxygen is restored, but DXV infected flies die off at a high rate after only an 
anoxic period of approximately 15 minutes (Figure 5).  Up until day five, DXV 
injected flies have a similar mortality rate after 15 minutes exposure to CO2 when 
compared to a control group injected with sterile water.  After the fifth day post-
infection, mortality increases and by day seven the infected flies have a 70% 






Figure 5.  DXV survival curves in Oregon R Drosophila melanogaster.  Control flies 
were not injected.  Water injected flies received only sterile water and food coloring.  
DXV flies were injected with 10-4 dilution of Drosophila-X Virus stock in sterile 
water and food coloring.  Graph shows percent surviving after 15 minutes exposure to 
CO2.   The anoxia sensitivity phenotype appears after day 5.  By day 10, nearly 95% 
























No injection Water injected DXV injected 
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infected flies fail to recover from anoxia (Zambon, unpublished).  The mechanism of 
this phenotype is unknown. 
 Drosophila infected with DXV have a shorter lifespan than flies injected with 
sterile water, living approximately two weeks even without anoxia exposure.  
Infected flies that do survive exposure to anoxia appear to exhibit a higher instance of 
defects in motility such as staggering, falling, and uncoordinated flying.  These 
defects are purely anecdotal and have not been quantified to any degree (Zambon, 
unpublished). 
DXV propagates to a moderate titer, accounting for approximately 0.1% of 
total protein in flies 5 days post-infection.  The primary experimental route of 
infection is injection.  The earliest experiments demonstrated that a 10-3 dilution of a 
filtered homogenate from infected flies was capable of producing infected flies that 
were anoxia sensitive after five days (Teninges et al., 1979).  In our laboratory, we 
have determined that injecting a 10-4 dilution is optimal when using a density gradient 
purified viral stock (Zambon, unpublished).   
Early attempts to demonstrate contact transmission appeared to show an 
effect.  Previously uninfected flies housed with those injected with DXV were 
homogenized.  The extracts were injected into other flies and 49 out of 130 were 
shown to produce anoxia sensitivity (Teninges et al., 1979).  More recently, using a 
more sensitive quantitative real-time PCR detection, we have been unable to 
demonstrate horizontal transmission (Zambon R, unpublished).  Injection/injury 
remains the only proven route of infection and is the method used in all our 
experiments. 
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Thin section staining of DXV infected flies with a polyclonal antibody against 
the virus has shown that the virus proliferates quickly throughout the hemolymph but 
does not appear to infiltrate the surrounding tissue such as the gut to a significant 




1.8  Infection in Cell Culture 
 
Drosophila-X Virus can propagate easily in cultures of Schneider-2 cells (S2), 
a line derived from Drosophila embryos.  Cells inoculated with DXV from either 
infected media or purified stock usually begin to exhibit typical cytopathic effects  
(CPE) after three days and viral proteins can be detected through western blotting.  
The CPE is characterized by blebbing of the cell membranes, cell death, debris, and 
occasionally a granular appearance to the cells. 
DXV can sometimes maintain a persistent infection in S2 cells which does not 
exhibit the typical cytopathic effects.  Though these cells appear uninfected, they are 
resistant to super-infection, failing to produce productive infections when inoculated 
with more virus (Teninges et al., 1979).  When subjected to western blotting with 
anti-DXV antibodies, persistently infected cells are shown to contain significant 





Materials and Methods 
 
2.1  Cell Lines 
 
Schneider-2 (S2) cells are derived from Drosophila melanogaster Oregon R 
strain embryos and were obtained from ATCC (American Type Culture Collection, 
Manassas, VA).  S2 cells were maintained in Schneider’s Drosophila Medium with L-
glutamine (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS) (Invitrogen).   Penicillin-Streptomycin (Invitrogen) was added 
for contamination control at a concentration of 50 units/L.  S2 cells were carried in 30 
mL of media in sealed-cap 75 cm2 tissue culture flasks at ambient temperature 
(~25°C).  Cultures were passaged every 3-5 days by washing confluent cells into the 
spent media.  An aliquot of S2 cells in this conditioned media was transferred into 
new flasks at a 1:5 dilution with fresh media.   
To obtain log phase cells for most experime nts, confluent flasks were split 1:5 
and allowed to grow for approximately 72 hours.  After 72 hours of growth, the 
confluent log phase S2 cells were gently washed from the bottom of the flask and 
transferred to a sterile 50 mL centrifuge tube.  One flask typically provided around 
107 or 108 cells, over 99% viable. 
 All baculovirus experiments were carried out in Sf9 cells, a line derived from 
Spodoptera frugiperda which grows in Grace’s Insect Media (Sigma-Aldrich Inc., St. 
Louis, MO) supplemented with 5% FBS (Invitrogen).  Sf9 cells are usually kept as 30 
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mL cultures in 75 cm2 flasks at 28°C.  Cultures would be washed from the bottom of 
the flasks and diluted 1:3 with fresh media each week to maintain the line.  As the 
cells do not grow to an adequately high titer under these conditions, suspension 
cultures were used to obtain large numbers of cells for experiments.  These were 
grown over several days as 150 mL cultures in spinner flask growth chambers at 28°C.  




2.2  DXV Growth and Propagation 
 
 All viral stocks were obtained from Robert Zambon and had been previously 
isolated and purified from infected S2 cells using CsCl density gradients (Zambon 
and Edwards, unpublished).  DXV stocks were stored in concentrated purified form in 
aliquots at -80°C.  Growth and propagation was carried out in S2 cells. 
 Primary viral inoculation stocks were produced by adding 50 µL concentrated 
DXV stock to fresh S2 cells in 25 cm2 tissue culture flasks.  At 7 days post-infection, 
once cytopathic effects (CPE) were observed, these cultures were centrifuged at 1000 
x g to remove most cellular material, and the DXV laden media was drawn off and 
stored at -20°C.  This inoculum was used a concentration of 1:60 to infect future 




2.3  DXV Injections 
 
 Adult Drosophila melanogaster were selected from stocks of the Oregon R 
strain.  Flies were taken approximately 1-5 days from eclosion and sedated on a 
porous pad connected to a CO2 supply.  Injections were by micropipette, held in an 
instrument crafted from a Leica Microsystems micromanipulator and a syringe that 
produces positive pressure.  Pipettes were pulled on a Kopf Model 730 Needle/Pipette 
Puller.  DXV was diluted to 10-5 in a solution of food coloring and water.  All 
injections were abdominal. 
 
 
2.4  RNA Isolation from Flies 
 
Total RNA, host and viral, was extracted from Drosophila and purified using 
RNA STAT-60 according to the published protocol (Isotex Diagnostics, Friendswood, 
TX).  In brief, samples were homogenized with an RNAse-free pestle in 500 µL of 
the phenol-based RNA STAT-60 reagent and incubated at room temperature.  100 µL 
of chloroform was added and the sample centrifuged to recover the aqueous portion.  
RNA was precipitated with 250 µL isopropanol and recovered by centrifugation.  The 
RNA was dried and resuspended in 20 µL sterile DEPC treated water.  Samples were 
quantified on a Thermo Spectronic BioMate3 spectrophotometer. 
A 3 µg sample of total RNA from each infected and control fly pool was 
transcribed to cDNA using reverse transcriptase PCR (RT-PCR) with 250 ng of 
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random hexamer primers.  This cDNA was resuspended in DEPC treated water and 
quantified (Sambrook et al., 1989). 
 
 
2.5  Real-time Quantitative PCR 
 
Real-time quantitative PCR (qPCR) was performed in an ABI PRISM 5700 
DNA Analyzer (Applied Biosystems) with data output to a Windows based computer.  
The qPCR reactions were carried out in optical 96-well 0.5mL plates.  FAM 
(carboxyfluorescein) fluorophore-labeled probes and primers were mixed with sterile 
water and qPCR Mastermix (Applied Biosystems, Foster City, CA) and aliquoted so 
each well received 10 pmol of each primer, 10 pmol of probe, and 12.5 µL of the 
mastermix in a total volume of 24 µL.  The cDNA from the previous reverse 
transcription was added in triplicate wells, and the reaction run for 30 cycles.  The 
data was analyzed in Excel (Microsoft Corporation, Redmond, CA). 
 
 
2.6  Polypeptide Antibody 
 
 The polypeptide sequence NH2-SRSHRRKKAKTRTKTSK-COOH from 
Drosophila-X Virus non structural protein was synthesized by Biosynthesis 
Incorporated (Lewisville, TX) and used to raise antibodies in rabbits (Figure 6).  The 







MLSIIRRKTRIVDITKQGNGNVPPACHLCSRRLTKEWSFG  1-40 
EGTICSFHRIRCRVQCGRSFWHQPETPIDGLSWDSTTWEL  41-80 
TRISSSKDPDISGQKDKRYGRRKEKNPKTDPPALDSRVRE  81-120 
HEPIHEHEPIPGRVGPADTKQRCKANLRGDSGFVSIGRSN  121-160 
HPKLSREDCHNTRVPPGTQGVRGGNVQLDKPRERPVSYQH  161-200  





Figure 6.  Anti-DXV-NS antibody epitope sequence.  The peptide epitope used to 
produce anti-NS antiserum in rabbits is highlighted in bold, residues 213 through 239. 
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2.7  SDS-PAGE and Western Blots 
 
 Polyacrylamide gel electrophoresis (PAGE) and western blots were produced 
though standard methods described here in brief.  SDS (Sodium Dodecyl Sulfate) 
denaturing gels were poured as 5%/10% stacking/resolving gels using a 30% mixture 
of acrylamide/bis 29:1 (Bio-Rad Laboratories, Hercules, CA).  Samples were heat-
denatured in PAGE loading buffer containing SDS and ß-mercaptoethanol (BME) by 
boiling for 5 minutes.  The protein samples were loaded and resolved by 
electrophoresis at 120 volts (Sambrook et al., 1989). 
 Those gels intended for total protein visualization were rinsed, stained with 
GelCode blue stain reagent (Pierce Biotechnology, Rockford, IL) for one hour, and 
destained with water for one hour. 
Samples intended for western blotting were transferred overnight at 40 volts 
onto nitrocellulose filters (Amersham Biosciences Corp, Piscataway, NJ).  Gel 
transfers were rinsed briefly in PBS and blocked in PBS with 0.1% Tween 20 and 5% 
nonfat milk for at least one hour or as long as overnight.  The primary antibody was 
diluted in PBS/Tween/5% milk and applied for one hour with gentle agitation on an 
orbital shaker.  The filters were washed four times in PBS/Tween for 5 minutes each 
followed by an incubation for one hour with the secondary antibody.  The horseradish 
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peroxidase (HRP) conjugated secondary antibody (Novagen) was diluted in 
PBS/Tween/5% milk.  The nitrocellulose filters were washed once again four times, 5 
minutes each, in PBS/Tween (Sambrook et al., 1989). 
 For visualization, the nitrocellulose filters were treated with enhanced 
chemiluminescent reagent (ECL) (Amersham) for one minute and exposed in a film 
cassette to ECL photographic film (Amersham) for one minute.  If necessary, 
additional exposures were carried out for 20 seconds to overnight, depending on 
signal strength (Sambrook et al., 1989). 
 
 
2.8  Cloning the Putative NS Protein 
 
 All cloning was carried out using standard molecular biology protocols 
(Sambrook et al., 1989).  Polymerase chain reactions (PCR) were performed for 30 
cycles in an MJ Research PTC-200 thermal cycler (South San Francisco, CA) using 
custom primers containing restriction enzyme cut sites and flanking the NS open 
reading frame.  Custom primers were obtained from both Gene Probe Technologies 
Inc. (Gaithersburg, MD) and Invitrogen (Table 2).  The template for these reactions 
was a clone of DXV segment A (DXVA) in a pUC19 vector previously engineered in 
our laboratory from our common DXV stock (Zambon R, unpublished).   
 All PCR transcripts were first cloned into the TOPO TA cloning kit 
(Invitrogen) according to the published protocol before being subcloned into an 



























Table 2.  Primers used in the construction of NS expression plasmids.  Sequences for 
the primers used to clone the DXV-NS inserts for each expression vector are given in 
the 5’ to 3’ direction along with the name. 
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µL pCR2.1-TOPO vector which comes linearized and activated with covalently 
bound topoisomerase vector.  The reaction volume was brought to 6 µL with sterile 
ddH2O and incubated at room temperature for 5 minutes to ligate.   
A 2 µL aliquot of the reaction was used to transform chemically competent 
TOP10F’ E. coli (Invitrogen).  Cells were incubated on ice for 30 minutes with the 
target plasmid, heat-shocked at 42°C for 30 seconds, and incubated with 250 µL SOC 
media at 37°C for 1 hour.  Cultures were spread onto XIA agar plates and incubated 
overnight.  White colonies were selected and cultured in 4 mL of Luria-Bertani broth 
with 50 µg/µL ampicillin (LB/AMP).   
 
 
2.9  Plasmid Recovery and Sequencing 
 
Plasmids were recovered with the Promega Wizard Plus Kits (Madison, WI) 
according to the published protocols.  The Mini kits were used for 3 mL of cultured 
material, while the Midi kits were used for cultures of 100 mL.  Final products were 
screened for the presence of the NS insert through restriction digest or PCR 
verification before being sequenced. 
All DNA sequencing was performed on-site by the staff of the Center for 
Biosystems Research DNA sequencing facility (College Park, MD) on a model 3100 




2.10  Subcloning into Expression Vectors 
 
 DXV-NS inserts were excised from pCR2.1 by enzyme digest at flanking 
restriction sites designed into the primers.  Vectors were linearized by restriction 
digest at the intended insertion site and if necessary, Calf Intestine Alkaline 
Phosphatase (CIAP) treated (Promega).  Cut vector and insert were gel purified from 
a 1% agarose gel using the QIAquick Gel Extraction Kit (Qiagen, Valencia, CA).  
Ligations were carried out according to standard protocol for T4 Ligase (Promega) 
and incubated overnight at 14°C.  Transformations were performed as described 
above in TOP10F’ cells and streaked onto LB/AMP agar plates.  Colonies were 
grown in LB/AMP as previously described.  Cultures were plasmid prepped and 
verified for the NS insert again as previously described. 
 
 
2.11  Expression Vectors 
 
DXV-NS was expresses as epitope tagged fusion proteins in four 
commercially available vectors (Figure 7).  The pET15b vector (Novagen) was used 
for DXV-NS expression in bacteria.  Expression in S2 cells was with pAc5.1/v5-His 
and pMT/v5-His which were provided as part of the Drosophila Expression System 
(DES) along with pAc5.1-lacZ control and pCoHygro selection plasmids 
(Invitrogen).  The pBlueBacHis2 transfer vector was used as described below to make 















Figure 7.  His-tagged DXV-NS recombinant expression products from four different 
vectors.  The V5 epitope was not used in these experiments.  The pET15b vector was 
designed for expression in E. coli.  The pAc5.1 and pMT plasmids were constitutive 
and metal-inducible insect expression vectors for Drosophila cells, respectively.  The 
transfer plasmid pBlueBac recombines with baculovirus genomic DNA in the 













2.12  Expression in BL21 Bacteria 
 
 Chemically competent BL21(DE3)pLysS expression strain E. coli 
(Stratagene, La Jolla, CA) were transformed with pET15b-NS expression vector.  In 
brief, approximately 1 µg of plasmid was added to a 50 µL aliquot of competent 
BL21 and incubated on ice for 5 minutes.  The reaction was heat shocked at 42°C for 
30 seconds and returned to ice with the addition of 250 µL SOC media.  After 
shaking in a 37°C incubator for one hour, 50 µL and 100 µL aliquots were spread 
onto LB/AMP agar plates and allowed to grow overnight at 37°C. 
 Colonies were picked from the plates and used to inoculate 50mL cultures of 
LB/AMP in 250 mL Erlenmeyer flasks.  The cultures were grown in a 37°C orbital 
shaker incubator to an optical density at 600 nm of 0.6.  Presence of the plasmid was 
confirmed by removing a small sample and assaying by PCR with the original 
primers.  Cultures were induced with the addition of either 0.4 mM or 1 mM IPTG 
and grown for an additional 3 hours. 
 The cultures were removed and placed on ice for five minutes, then pelleted at 
5000 x g for 5 minutes.  The cells were resuspended in 12 mL of ice cold 20 mM Tris 
HCl pH 8.0 and centrifuged again for 5 minutes at 5000 x g.  The pelleted cells were 
frozen at -70°C and thawed to self-lyse.  Samples were run on SDS-PAGE gels and 
either stained for protein or used for western blots as described previously (Sambrook 




2.13  Plasmid Stability Assay 
 
 Plasmid stability was tested as outlined in the pET expression system 
literature (Novagen).  50 mL cultures of pET15b-NS in BL21(DE3)pLysS were 
grown in LB containing carbenicillin.  After reaching OD600 0.6, a sample from each 
was diluted to 10-6 and spread on LB agar plates with and without carbenicillin.  A 
10-5 dilution of each culture was streaked onto LB agar plates containing IPTG, again 
with or without carbenicillin. 
 
 
2.14  Increasing Plasmid Stability 
 
 The protocols for increasing plasmid stability were outlined in the pET 
expression system literature (Novagen).  A 2 mL starter culture was prepared with 
200 µg/mL carbenicillin and grown for 3 hours at 37°C until the OD600 reached 0.6.  
The culture was centrifuged at 5000 x g for 5 minutes and resuspended in 2 mL fresh 
media.  A 100 µL aliquot was taken and added to 8 mL of LB containing 500 µg/mL 
carbenicillin.  The fresh culture was grown for 2.5 hours to OD600 0.45 and once 
again spun down.  The pellet was resuspended in 8 mL LB with 500 µg/mL 





2.15  Transfection of S2 Cells 
 
 Drosophila S2 cells were transfected using the lipid-based reagent CellFectin 
in a protocol adapted from the published procedure (Invitrogen).  Log phase cells of 
at least 95% viability were centrifuged at 1000 x g and the supernatant removed from 
the cell pellet by aspiration.  Cells were resuspended in serum-free media without 
antibiotics and quantified using a hemacytometer and trypan blue stain to determine 
viability.   
 Cells suspended in serum-free Schneider’s media were added to 6-well plates 
at approximately 3 x 106 cells per well.  The total volume per well was 3 mL.  The S2 
cells were placed in a sealed container to maintain humidity and prevent evaporation 
and incubated at 28°C for at least one hour to allow attachment. 
 Plasmid DNA was sterilized by ethanol precipitation.  In brief, 3M sodium 
acetate was added to the DNA the previous day at a ratio of 1/10 the total volume and 
mixed well.  Three volumes of ethanol were added to the DNA and mixed.  The 
solution was precipitated overnight at -20°C and the DNA recovered by 
centrifugation.  The DNA pellet was dried, resuspended in sterile ddH2O and 
quantified.  The concentration was brought to 1 µg/µL with more sterile water. 
 For each transfection, 2 µg of the plasmid DNA was added to 250 µL of 
serum-free media.  In a separate tube, 8 µL of the CellFectin reagent was diluted in 
250 µL serum-free media.  The two solutions were mixed well separately, combined, 
and mixed well together.  The solution was incubated at room temperature for 20 
minutes.  The transfection mixture was then diluted with a further 800 µL of serum-
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free media.  Media was aspirated from the wells and the dilute transfection mixture 
slowly overlaid on the cells. 
 The cells were incubated at 28°C for 3-4 hours and the transfection mixture 
aspirated from the wells.  The cells were washed once with serum-free media and 
then left overnight at 28°C in fresh serum-free media.  
 
 
2.16  ß-Galactosidase Control Assay 
 
 S2 cells were transfected as previously indicated with pAc5.1-lacZ.  Two days 
after transfection, the media was aspirated and the cells rinsed with PBS.  The cells 
were fixed at room temperature for ten minutes in a 2% solution of glutaraldehyde in 
PBS.  The fixing agent was removed by aspiration and the cells rinsed twice with 
PBS.  A solution of 1 mg/mL X-gal in stain solution (0.01 M sodium phosphate 
buffer pH 7.2, 0.15 M NaCl, 1 mM MgCl2, 3.1 mM K4[FeII(CN)6], 3.1 mM 
K3[FeIII(CN)6], 0.3% Triton X-100) (Wu et al., 2001), was added to the cells and 
incubated for 1 hour at 37°C.  Cells were visualized using bright field on an inverted 
microscope for blue staining. 
 
 
2.17  Metallothionein Induction in pMT Plasmid 
 
 At one day after transfection, a solution of sterile CuSO4 was added to the 
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media at a concentration of 500 µM as indicated in the DES literature (Invitrogen).  
Copper-induced cells were collected 2, 3 and 4 days post-induction.  The cells were 
collected by washing them from the wells and centrifuging them in microcentrifuge 
tubes.  The media was removed and saved while the pellets were washed once with 
PBS.  Both media and cell pellets were flash-frozen and stored at -80°C. 
 
 
2.18  Selection of Stable Cell Line Expressing DXV-NS 
 
 Drosophila S2 cells were dual-transfected with pAc5.1 vector containing the 
DXV-NS insert and pCoHygro hygromycin-B selection plasmid in a 20:1 ratio.  The 
transfection protocol was as indicated before except using 8 µg of the 
pAc5.1/pCoHygro mi xture and 16 µL CellFectin reagent.  Following transfection, the 
cells were switched to Schneider’s media with 10% serum and incubated at 28°C for 
5 days. 
 On the fifth day, the media was aspirated and replaced with selection media, 
Schneider’s media with serum and 500 µg/mL hygromycin-B.  The selection media 
was replaced every 3-5 days until resistant cells began to grow.  Once the wells were 
confluent, resistant cells were expanded to a 25cm2 flask and eventually to 75 cm2 
flasks.  Once established, cells were maintained as other S2 cells except in media 




2.19  Expression in Baculovirus 
 
 Transfections were carried out according to the protocols in the Bac and Blue 
system (Invitrogen).  In brief, log phase Sf9 cells from a spinner culture 
approximately a week old were plated in 6-well plates, 2 x 106 cells per well.  The 
cells were incubated for 15-60 minutes at 28°C to allow attachment.   
 The transfection reaction was prepared by adding 1 µg of ethanol precipitated 
pBlueBacHis2-NS transfer vector to one tube containing 0.5 µg Bac-and-Blue DNA 
from the transfection kit (Invitrogen).  A 20 µL aliquot of CellFectin transfection 
reagent and 1 mL Grace’s media without serum were added to the genetic material 
and the reaction was incubated at room temperature for 15 minutes.  The cells were 
washed once with Grace’s media without serum and the media removed and replaced 
with the transfection reaction.  The Sf9 cells were incubated at room temperature for 
4 hours on a side-to-side rocker at which time 1 mL of complete Grace’s media 
containing 5% serum was added to the wells.  The plate was placed in a sealed 
container to prevent evaporation and incubated for 72 hours at 28°C. 
 On the third day post infection, the media was removed and saved and 3 mL 
of fresh media placed on the cells for an additional day.  This was repeated at day 4 
and the final aliquot of media collected at day 5.  When compared to a control well of 
uninfected cells, the baculovirus infected Sf9 cells will begin to exhibit cytopathic 
effects between days 3-5 post transfection characterized by swelling, granular 
appearance and eventually lysis. 
 The day 3, 4 and 5 media inoculates contained shed baculovirus and were 
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plaque purified and selected for expression of the DXV-NS insertion gene.  Each 
inoculate was initially tested in tenfold serial dilutions from 10-2 to 10-9, each on a 
single dish to determine the optimum concentration range to get proper plaque 
formation. 
Sf9 cells were grown to log phase as described before and plated into 100 mm 
culture dishes at 50% confluence–approximately 5 x 106 cells per dish–in 5 mL of 
Grace’s Insect Media containing 5% FBS.  The cells were allowed to attach for 
approximately one hour and 3 mL of the media were removed and replaced with 1 
mL of the serial baculovirus inoculate dilution.  The virus was allowed to infect the 
cells for one hour. 
The overlay media was prepared while the cells were being infected.  Sterile 
2.4% low temperature melting agarose was melted and equilibrated to a temperature 
of 47°C in a water bath.  An equal volume of 2x Graces Insect media (Invitrogen) was 
prepared and supplemented with 5% serum and 150 µg/mL of sterile X-gal 
chromogenic substrate.  Once the infection incubation was complete, the media was 
aspirated from the dishes as thoroughly as possible.  The overlay was prepared by 
mixing 5 mL each of the 2x agarose and the 2x Graces media and pipetting it gently 
over the cells. 
Once the agarose had set, the dishes were incubated in a sealed container at 
28°C and checked daily.  Excess moisture in the container was removed to prevent 
disruption of the cell monolayer and the plates were visualized under an inverted 
microscope for presence of plaque formation and blue coloration that would indicate 
the presence of recombinant plaques. 
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Once optimal dilutions were established, the assay was repeated using 5-8 
dishes at the optimum recombinant baculovirus concentration for proper plaque 
formation.  The protocol was as described above.  Recombinant plaques with a blue-
green indicator color were selected and transferred into 25cm2 flasks of log phase Sf9 
cells.  The infectious media was removed and saved while the cells were assayed by 
western blotting for presence of the DXV-NS protein. 
 
 
2.20  Frameshift Signal 
 
 Analysis for a “slippery site” sequence upstream from the DXV-NS open 
reading frame was with PERL script software search algorithms written by Jonathan 
Jacobs.  An oligonucleotide segment containing the putative signal was synthesized 
by Integrated DNA Technologies, Inc (Coralville, IA) (Figure 8).  The pJC175f dual 
luciferase reporter plasmid was donated by Jonathan Dinman. 
 The complementary strands of the signal oligonucleotide, 4.5 µg of each, were 
heated to 70°C in annealing buffer (20 mM Tris-HCl pH 7.4, 2 mM MgCl2, and 50 
mM NaCl2) and cooled to room temperature.  The annealed insert was purified from a 
5% gel of low boiling point agarose.  The purified insert was ligated into pJC175f and 

















Figure 8.  Frameshift sequence oligonucleotides.  Two complementary 75-mer 
oligonucleotides were designed incorporating the dual overlapping slippery sites 
(bold) and stem loop found upstream from the DXV-NS ORF (underlined start 
codon).  When annealed, the two oligonucleotides form an insert with sticky ends for 








3.1  Quantitative PCR Detects Relative DXV Titer In Infected Drosophila 
 
 Previous attempts by our group to quantify Drosophila-X Virus titer through 
the common plaque assay method had been unsuccessful; the S2 cells did not 
maintain fixed monolayers in plaque assays.  Instead, quantitative real time PCR 
(qPCR) was developed as an alternative method to quantify increases in infection 
based on viral genome load.  We designed a custom primer-probe set (Applied 
Biosystems) which targeted a sequence towards the center of the DXVA segment. 
 Wild-type Oregon R Drosophila melanogaster were injected with a 10-4 
dilution of DXV in a mixture of sterile water and food coloring.  This concentration 
was previously determined to be an optimal viral load for infection, leading to onset 
of symptoms at approximately five days post infection and eventually maximum 
anoxia sensitivity die-off at ten days (Zambon, unpublished).  The control group 
received an injection of water and dye only.  Both groups consisted of 60 adult flies.   
 Five live flies were collected, pooled, and flash frozen from both the infected 
and control group on days 0, 1, 3, 5, 7.  Total RNA was extracted as described 
previously and subjected to RT-PCR.  The cDNA was run through qPCR in two sets, 
one with the primers and FAM phosphor labeled probes against DXV segment A and 
the other with a control probe set against the Drosophila gene RP49 (Applied 
Biosystems).  Each data point was run in triplicate. 
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 An equal amount of RNA isolate from each data point had been used in the 
RT-PCR, but obviously the proportion of viral to host RNA would vary greatly.  Each 
sample had to be normalized, and that was accomplished by comparing the 
quantification of RP49 gene expression, the large ribosomal subunit.  This gene is 
used as a standard for expression in Drosophila since it is expressed at a relatively 
constant level.  By equilibrating to a standard count of host cDNA, a more accurate 
measure of DXV signal between samples could be taken.  DXV counts at time-point 
zero, which are flies harvested immediately following injection, served as the 
baseline from which to measure fold induction of viral titer. 
 The results show the dramatic progression of DXV in the fly.  Viral titer 
increases dramatically after the first day of infection, peaking at day five.  Even 
though we can see the titer has reached approximately 80% of maximum by day three, 
the anoxia sensitivity phenotype does not begin to show until day five (Figure 9). 
 Although this method does not provide an absolute quantification of viral 
titer—we have not been able to assign a numerical value such as infectious units—it 
does allow us to assess relative levels of virus in the fly over the course of an 
infection.  This enables us to correlate anoxia sensitivity to virus load in flies. 
 
 
3.2  Antibodies Developed to Detect Endogenous and Recombinant DXV-NS 
 
 As no commercially available antibody exists against Drosophila-X Virus, 
suitable antisera was developed by Robert Zambon, a graduate student in our lab. 
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Figure 9.  Increase in Drosophila-X Virus titer over time in flies.  Control flies were 
injected with water and DXV infected flies were injected with a 10-4 dilution of virus.  
Flies were collected at day zero immediately following injection and again at days 1, 
3, 5, and 7.  RNA was extracted from a pool of 5 flies at each time point and passed 
through RT-PCR and qPCR with primers against DXV and Drosophila RP49.  
Samples were normalized against RP49 levels and the arbitrary DXV signal counts 
graphed against time. 
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The anti-DXV serum contains polyclonal antibodies raised against whole and 
fractionated DXV in rabbits.  When used in western blotting to detect infection, anti-
DXV detects three distinctive bands–49, 45, and 34-kDa.  These correspond to the 
known sizes of pVP2, VP2, and VP3 respectively and provide an accurate indicator 
of DXV infection. 
Two anti-His tag antibodies were used.  Anti-His(c-term)-HRP was the first 
used, a horseradish peroxidase conjugated monoclonal antibody raised in mouse 
against a c-terminal His6 tag (Invitrogen).  This was eventually found to be of poor 
quality, and later experiments used a mouse anti-His antibody from Novagen. 
Since Drosophila-X Virus Non-structural protein had never been detected, 
there were no available anti-NS antibodies.  The projected amino acid sequence for 
DXV-NS was analyzed for antigenicity and a portion towards the C-terminus 
(residues 212 to 228) of the putative protein was selected for immunization.  This 
antiserum was used in concert with anti-His antibodies in attempts to identify 
recombinant DXV-NS as well as evidence of the protein in infected S2 cells.  
The anti-NS antibody was unable to detect NS in infected S2 cells or infected 
homogenized Drosophila in western blots.  Despite assaying infected cells and 
homogenized infected flies at a number of time points up to seven days, there were no 
discernable differences in protein band staining between lanes containing uninfected 
material and those lanes with infected material.  DXV-NS was also not detected in the 




3.3  Expression of Recombinant DXV-NS in Four Vectors  
 
 Drosophila-X Virus NS is a putative protein, never detected in virions or 
infected flies or cells.  It was necessary to produce a recombinant form of the protein 
to use as a tool in our research.  A purified, tagged form of the protein would be 
useful as a standard as well as a possible antigen for production of an antibody.  
Forms of DXV-NS suitable for expression in Drosophila cells could be useful to 
examine the effects of the protein in the host as well as subcellular localization. 
 Four constructs were produced; each designed to express a His-tagged form of 
DXV-NS in different hosts or under various promoters.  The pET15b vector was 
designed for high-yield expression in E. coli.  The pMT and pAc5.1 plasmids were 
metal-inducible and constitutive insect expression vectors respectively.  The transfer 




3.4  Lack of DXV-NS expression in BL21 E. coli 
 
High-yield expression of DXV-NS was first attempted in Escherichia coli.  
Successful expression would have provided a purified form of the protein to use as a 
standard to test the efficacy of the DXV-NS antiserum as well as material that could 
potentially be used as inoculum to generate a new antibody.  The NS ORF was cloned 
into pET15b (Novagen) a ß-galactosidase/lac driver system vector which also 
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appends an N-terminal His6 tag.  The ORF was PCR amplified from DXVA and 
ligated into pCR2.1 TOPO as described above.  The NS insert was excised with BglII 
at restriction sites designed into the flanking primers (Figure 10) and gel-purified 
using the QIAquick Gel Extraction Kit (Qiagen, Valencia, CA).  The insert was non-
directionally ligated into a complementary BamHI site in pET15b (Figure 11). 
 The presence and orientation of the NS insert was verified through differential 
cutting restriction enzyme digestion using an EcoRI site in the vector and a BamHI  
site in the 146 base pair position of the 714 bp insert.  The correct orientation would 
yield an 889 bp piece, while the reverse would produce a 467 bp cut.  Properly 
oriented pET15b-NS constructs were confirmed through sequence analysis and 
transformed into BL21(DE3)pLysS E. coli. 
 The pET15b system alters the N-terminal end of the target protein with the 
His tag and uses its own promoter and initiation site, therefore eliminating one 
variable from protein expression.  However, initial attempts at expression failed to 
produce any over-expressed proteins.  Comparison on a protein stained PAGE gel of 
untransformed Bl21 cells and cells induced with either 0.4 or 1 mM IPTG showed no 
difference in banding and no over-expressed band typical of such high yield protein 
expression systems (Figure 12).  Subsequent ECL western blotting with anti-His 
antibody (Novagen) failed to produce anything except background. 
 Initial troubleshooting failed to produce different results.  IPTG dosage from 
0.4 mM to 1 mM had no effect; neither did varying the method of culture inoculation.  
50 mL cultures were initiated from glycerol stocks, colonies on freshly streaked 












pET15b Forward priming site 
 















Figure 10.  Forward and reverse priming sites for pET15b-NS construct.  The forward 
and reverse primers insert BglII restriction sites (boxes) flanking the DXV-NS ORF 
(bold).  When inserted in the proper orientation at complementary overhangs 
produced at a BamHI restriction site in pET15b, this maintains an in-frame fusion 






























Figure 11.  Multiple cloning site and plasmid diagram for pET15b.  DXV-NS inserts 
at the BamHI restriction site, creating an N-terminal fusion with the His6 epitope tag.  










Figure 12.  BL21 cells with the pET15b-NS expression construct.  This ECL western 
blot with 1:750 concentration of anti-His antibody (Novagen) fails to show any 
difference between the control and induced cells.  Lane A: Untransformed BL21.  
Lane B: BL21 with pET15b-NS, induced with 0.4 mM IPTG.  Lane C: BL21 with 
pET15b-NS, induced with 1 mM IPTG.  Protein molecular weight standards are in 
kDa.  The predicted size of NS is 27-kDa 
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established protocol expected a 50 mL culture from a single colony to reach OD600 by 
3 hours, cultures of pET15b-NS were taking five hours or longer to reach the target 
density.  This retardation of growth could have been a result of plasmid instability 
due to toxicity of the expressed protein. 
 To test for plasmid instability, two new 50 mL cultures were grown for 
pET15b-NS in BL21(DE3)pLysS using more stable carbenicillin as the selection 
agent rather than ampicillin.  The cultures were inoculated directly from a colony on a 
freshly streaked plate and from a 2 mL starter culture.  After growing to OD600 0.6, a 
sample from each was diluted to 10-6 and spread on LB agar plates with and without 
carbenicillin.  A 10-5 dilution of each culture was streaked onto LB agar plates 
containing IPTG, again with or without carbenicillin. 
 For a typical culture suitable for high yield expression, nearly all cells should 
grow on plates containing antibiotic as well as the plain agar plates.  Less than 2% 
should grow on the IPTG plate since only cells that have lost the plasmid should 
grow.  The plate with both IPTG and antibiotic restricts growth to cells that have 
retained the plasmid and selection marker but lost ability to express the target gene 
and should allow less than 0.01% to grow. 
 From the results, it would initially appear that the plasmid is relatively stable 
(Table 3).  Both the plain agar plate and the one containing carbenicillin have greater 
than a thousand colonies, while the IPTG and IPTG/CARB plates number in the 
hundreds.  However, pET15b-NS is a T7/lac promoter construct and was grown in a 
BL21 strain containing the pLysS plasmid, both of which are factors which can 








agar only ++ ++ >99%
CARB ++ ++ >99%
IPTG 650 233 <2%






Table 3.  Plasmid stability assay results.  BL21 cells with pET15b-NS showing 
number of colonies per plate.  The notation ++ indicates several thousand, too 
numerous to count.  In a culture suitable for overexpression of the target gene, nearly 
all cells are expected to grow on agar and carbenicillin only plates.  Less than 2% 
should form colonies on plates containing only IPTG and less than 0.01% should 
grow on plates with both IPTG and the selection agent. 
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was carried out despite the ambiguous results to see if it had any effect on the NS 
expression. 
The plasmid stability assay, as described in the methods, is designed to 
replace the growth media several times with increasing levels of carbenicillin, up to 
five-fold of the standard protocol.  Carbenicillin is a more stable analog of ampicillin 
and changing the media gets rid of the secreted ß-lactamase, the enzyme which breaks 
down the selection antibiotics and confers resistance. 
Despite following this protocol, results were identical.  There were no changes 
in protein expression compared with control BL21 cells.  Since other DXV-NS 




3.5  Lack of DXV-NS expression from pMT metallothionein-driven vector 
 
 Expression of DXV-NS in Drosophila S2 cells was first attempted using 
pMT/V5-His (Invitrogen), an insect vector driven by the metallothionein promoter 
and designed to express the gene of interest as a fusion protein with C-terminal V5 
and His6 epitope tags.  Since it was unknown whether NS would be toxic to the cell 
or degraded quickly, it was important that expression in S2 cells first be attempted 
with a vector that allowed inducible expression. 
NS was PCR amplified from DXVA with a forward primer containing an 
EcoRI site.  The reverse primer was designed to eliminate the double stop codons at 
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the end of the NS reading frame as well as adding an XbaI cut site (Figure 13).  The 
reverse primer also maintained the same frame with the C-terminal tags and stop 
codon in the vector.  The final NS fusion protein would retain its original sequence 
with the addition of 29 residues from the vector at the C-terminal end (Figure 14). 
The NS insert was directionally ligated into pMT at corresponding EcoRI and 
XbaI restriction sites.  The final product was verified by sequencing.  The pMT-NS 
plasmid was transfected into S2 cells according to the standard protocol alongside 
wells containing pAc5.1-lacZ reporter plasmid as a transfection positive control.  
Staining of the reporter wells with X-gal indicated approximately 20-30% efficiency 
in the transfection, a value which we would find consistent throughout experiments 
with S2 cells. 
The transfected cells were induced with the addition of 500 µM CuSO4 and 
collected for three days.  Western blotting with both anti-His (Invitrogen) and anti-NS 
antibodies revealed only background, no change in comparison to untransfected S2 
cells. 
Since this plasmid was an inducible vector this added an additional 
complication to the expression of DXV-NS.  It could not be determined whether the 
lack of expression was in some flaw of design, a problem with induction, or that the 
cells simply had difficulty expressing this protein.  With too many variables, a 
constitutively active insect vector, pAc5.1 was investigated to eliminate the induction 















pMT-NS Forward priming site 
 















Figure 13.  Forward and reverse priming sites for pMT-NS construct.  The priming 
sites flank the DXV-NS ORF (bold).  The forward primer inserts an EcoRI restriction 
site (box).  The reverse primer removes the double stop codon (underlined) at the end 
of the DXV-NS ORF and adds an XbaI restriction site (box).  When inserted at the 
corresponding XbaI restriction site in pMT(b), this maintains an in-frame fusion with 
















Figure 14.  Multiple cloning site and plasmid diagram for pMT/V5-His.  DXV-NS 
inserts in a directional manner at EcoRI and XbaI restriction sites, creating a C-
terminal fusion with the V5-His6 epitope tags and stop codon.  Expression is driven 
by the pMT promoter. 
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3.6  Expression of DXV-NS in stably transfected S2 cells  
 
 The use of a constitutively active insect vector was important to eliminate the 
variable of induction from attempts to express DXV-NS protein.  The pAc5.1/V5-His 
vector is designed to express a gene of interest as a fusion protein with a C-terminal 
tag containing the V5 and His6 epitopes (Invitrogen).  The promoter is constitutively 
active in all Drosophila cell types, including S2.  Eventually, this expression construct 
was scaled up by producing a stable line.  As with pMT, the pAc5.1 system has the 
advantage of expressing DXV-NS in Drosophila, its natural host. 
 Initial cloning into pCR2.1-TOPO was as described previously, but modified 
with an additional mutation step (Figure 15).  The pAc5.1 plasmid required a Kozak 
sequence in the form 5’-G/A-NNATGG-3’ to enhance expression, but the NS 
sequence had a cytosine instead of a guanine in the +4 position.  To ensure proper 
expression, the NS start sequence was first point-mutated from 5’-ACC-ATG-CTA-3’ 
to 5’-ACC-ATG-GTA-3’ at the +4 bp position with a second forward primer.  The 
change results in a substitution of a valine for a leucine that, while not a silent 
mutation, is a relatively neutral alteration of two biochemically similar residues. 
The altered insert in pCR2.1 was used as a template for the second round of PCR with 
the second forward primer that added an upstream KpnI cut site outside the start 
codon.  The reverse primer eliminated the double stop codons at the 3’ end of the NS 
ORF and inserted an ApaI restriction site, in frame with the C-terminal fusion 

























Figure 15.  Priming sites in two-step PCR reaction for pAc5.1-NS construct.  The 
mutation primer first creates a point mutation at the +4 position, changing the Kozak 
sequence to a form that fits the required 5’-G/A-NNATGG-3’ motif.  In the second 
step, the priming sites flank the DXV-NS ORF (bold).  The forward primer inserts a 
KpnI restriction site (box).  The reverse primer removes the double stop codon 
(underlined) at the end of the DXV-NS ORF and adds an ApaI restriction site (box).  
When inserted at the corresponding ApaI restriction site in pAc5.1(b), this maintains 
an in-frame fusion with the downstream epitope tags and stop codon contained in the 
vector.   
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double digest and directionally subcloned into the corresponding restriction sites in 
pAc5.1 (Figure 16).  The completed plasmid was sequenced for verification. 
 Wells of S2 cells were transfected with either pAc5.1-NS or the pAc5.1-lacZ 
control plasmid.  When stained, the control indicated approximately 30% transfection 
efficiency.  The cells were harvested and flash frozen over several days and analyzed 
through western blotting with anti-His (Novagen) and anti-NS antibodies.  Once 
again, there was only background and no discernable difference between cells with 
and without the plasmid. 
 It seemed possible that expression was occurring in only a few cells or at 
extremely low levels since despite the successful transfection, no protein could be 
detected.  Since individual transfections were an inefficient method of producing 
protein, the process was scaled up by creating a stable cell line with the pAc5.1-NS 
construct. 
 The stable line was created with a co-transfection of S2 cells with pCoHygro 
and an excess of pAc5.1-NS.  The pCoHygro is a selection plasmid conferring 
resistance to hygromycin-B and is transfected in a 1:20 proportion with the vector so 
as to ensure that nearly all cells that receive the selection plasmid also receive the 
expression vector.  Cells were selected and expanded according to the protocol 
indicated previously for approximately 6 weeks, resulting in a confluent 75cm2 flask 
of S2 cells with the pAc5.1-NS plasmid.  These cells were used as a polyclonal 
culture since dilution to single cells to create a monoclonal culture was not possible 



















Figure 16.  Multiple cloning site and plasmid diagram for pAc5.1/V5-His.  DXV-NS 
inserts in a directional manner at KpnI and ApaI restriction sites, creating a C-
terminal fusion with the V5-His6 epitope tags and stop codon.  Expression is driven 
by the pAc5 promoter. 
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spread too thin will not grow and divide.  It took several attempts before successful 
polyclonal stable cultures were established after the initial die-off. 
These cells were maintained in Schneider’s complete media containing 500 
µg/mL hygromycin-B.  These cells, while apparently healthy with no changes in 
growth, do appear to have some physical changes.  Compared to normal S2 cells, the 
stable NS line cells tend to clump a bit more and have poor adhesion to the surface of 
a flask or well, though this may be an effect of the selection agent. 
 A large number of cells (10 mL of a confluent flask or approximately 107 
cells) were centrifuged and lysed to form a cell concentrate.  Denatured by boiling 
and resolved on a PAGE gel, this concentrate was blotted with anti-His (Novagen) 
and anti-NS.  A distinct band was revealed at approximately 30-kDa with both 
antibodies, consistent with the epitope tagged fusion NS protein (Figure 17). 
 It appears that NS is being produced by the pAc5.1-NS construct, but at very 
low levels.  The reason for this result is unknown.  Toxicity is a possible answer, but 
if so, the protein does not appear at these low levels to be lethal enough to cause 
widespread death in S2 cells since the stable line appears to maintain the same greater 
than 99% viability as normal cells.  Perhaps high expression is toxic and this has 
selected for variants which express NS only at low levels.  Without determining what 
percentage of cells express protein, it is also possible that most have lost the 
expression plasmid while retaining the selection plasmid.  It is possible that future 









Figure 17.  Expression of constitutively active pAc5.1-NS construct in S2 cells.  ECL 
Western blot with a 1:1000 dilution of anti-His antibody (Novagen).  Lane A: 
Untransfected S2 cells.  Lane B: S2 cells, stable transfected line with pAc5.1-NS.  
Protein standards are in kDa.  There is an expressed protein in the transfected cells 





3.7  Expression of DXV-NS from recombinant Baculovirus 
 
 Expression of DXV-NS using a recombinant baculovirus system was 
developed concurrently with the pAc5.1 constitutively expressing system.  The vector 
pBlueBacHis2 is a transfer vector designed for use with the Bac-and-Blue 
transfection kit as a complete system for the cloning and expression of a gene of 
interest in a recombinant baculovirus (Invitrogen).  The system expresses this gene as 
an N-terminus fusion with the His6 tag for easy identification.  Recombinant 
baculoviruses containing the inserted gene of interest will also have an active ß-
galactosidase indicator gene and will result in blue plaques in the presence of X-gal. 
 The NS reading frame was PCR amplified from the DXVA clone using 
flanking primers designed with BglII and EcoRI directional restriction sites (Figure 
18).  As described before, the insert was ligated into pCR2.1-TOPO and excised at 
the restriction sites.  The NS ORF was cloned in frame into pBlueBacHis2, lining up 
with the vector-provided initiation site and His tag (Figure19).  Vectors were grown 
and isolated as indicated before and verified by restriction digest and sequencing. 
 During transfection, the pBlueBacHis2 transfer plasmid carrying the DXV-
NS/His fusion gene recombines with the baculovirus genomic DNA from the kit at 
homologous transfer points designed into the two pieces of DNA.  The resulting 
recombinant baculovirus is collected from the media and plaque purified.   
 Recombinant virus with the inserted gene of interest will express ß-
galactosidase and stain blue in the presence of media containing X-gal.  Blue staining 
of plaques and surrounding agarose in the plates was observed, indicating successful   
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pBlueBacHis2C Forward priming site 
 
        5’-AGATCTCATGCTATCAATTATTAGAAGGAAG-3’ 
5’-AAATTTTTTAAGAAGCGATTACATCCTCCTACCATGCTATCAATTATTAGAAGGAAGACT-3’ 
3’-TTTAAAAAATTCTTCGCTAATGTAGGAGGATGGTACGATAGTTAATAATCTTCCTTCTGA-5’ 
   
 










Figure 18.  Forward and reverse priming sites for pBlueBacHis2c construct.  The 
priming sites flank the DXV-NS ORF (bold).  The forward primer inserts a BglII 
restriction site (box) and the reverse primer adds an EcoRI restriction site (box).  
When inserted at the corresponding BglII restriction site in pBlueBacHis2c, this 














Figure 19.  Multiple cloning site and plasmid diagram for pBlueBacHis2c.  DXV-NS 
inserts in a directional manner at BglII and EcoRI restriction sites, creating an N-
terminal fusion with the His6 epitope tag.  The BlueBac transfer vector recombines 
with genomic baculovirus DNA in the Bac and Blue kit (Invitrogen) to form 
baculovirus expressing the NS gene. 
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recombination.  Six plaques were isolated and expanded in 25 cm2 flasks of Sf9 cells.  
Western blots of these infected cells with a 1:1000 dilution of anti-His antibody 
(Novagen) and 1:750 anti-NS revealed an identical strong band at approximately 27-
kDa, the expected size for the His-DXV-NS fusion protein (Figure 20). 
 
 
3.8  DXV-NS contains a putative upstream frameshift signal 
 
 The DXV-NS ORF is located in the middle of segment A, its start sequence 
overlapping the coding region for the polyprotein.  If the NS protein is made by 
Drosophila-X Virus, it is possible that this is accomplished through programmed -1 
frameshifting.  We investigated whether the sequence upstream from NS contained a 
-1 PRF site. 
 The nearest upstream stop codon in the -1 frame is -72 bases from the DXV-
NS ORF, so any slippery site must be downstream of this point.  The region was 
analyzed using software and search algorithms designed by Jonathan Jacobs.  Two 
overlapping slippery sites were found upstream from the start of the NS ORF: 5’-A 
AAU UUU-3’ at the -33 position and 5’-U UUU UUA-3’ starting at -30.  This signal 
was followed by a spacer (7 or 4 nucleotides for the respective sites) and a substantial 
stem-loop (Figure 21).  Although no RNA modeling configuration was found in 
which the stem-loop formed a pseudoknot, this does not necessarily mean that such a 
structure does not exist.  The relative strength of the slippery site combined with the 





Figure 20.  Expression of DXV-NS/His fusion protein from recombinant baculovirus.  
Lane 1: Uninfected Sf9 control.  Lanes 2-7: Recombinant Baculovirus isolates 1-6.  
Part A:  Western blot with 1:1000 anti-His (Novagen).  Part B: Western blot with 




















Figure 21.  Portion of DXVA genome showing -1 PRF site.  The 5’-A AAU UUU-3’ 
slippery site (bottom bracket) is separated from the stem loop by a 7 nt spacer and is  
-33 nt upstream from the start of the DXV-NS ORF.  The 5’-U UUU UUA-3’ 
slippery site (top bracket) is separated from the stem loop by a 4 nt spacer and is -30 
nt upstream from the start of the DXV-NS ORF. 
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 The sequence for the slippery site and stem loop discovered in this search was 
incorporated into a pair of 75-mer oligonucleotides from Integrated DNA 
Technologies Inc. (Coralville, AI) which were complementary but with overhanging 
ends that matched restriction enzyme sites in a SalI to BamHI direction.  The two 
oligonucleotides were annealed and gel purified to form the slippery site insert. 
The plasmid pJD175f was used for the frameshifting reporter.  Obtained from 
the laboratory of Jonathan Dinman, it consists of a modified p2luc vector 
(Grentzmann et al, 1998).  A T7 promoter drives expression of sequential Renilla 
luciferase (rluc) and firefly luciferase (fluc) genes.  A polylinker site between the two 
allows insertion of the slippery site sequence so that fluc is in a -1 frame from rluc 
and requires -1 frameshifting to be expressed.  The ratio of firefly to Renilla 
luciferase reveals what percentage of translation events result in a slip and -1 
frameshift. 
The pJD175f reporting vector was cut at the polylinker with SalI and BamHI.  
The insert containing the putative slippery site and stem loop upstream from DXV-
NS was directionally ligated into the vector and the completed reporter construct 
transformed and grown in TOP10F’ E. coli as described above.  Plasmids were 
purified from culture and verified via sequencing. 
This frameshifting construct will be a useful future tool in the further study of 
DXV-NS.  If the slippery site does not produce a -1 frameshift, it is unlikely that this 
is the method of expression for NS and other translation schemes involving motifs  




Discussion and Conclusions 
 
4.1  Conclusions 
 
 In the course of this thesis work, there were some successes which resulted in 
the creation of a number of useful tools for the further study of Drosophila-X virus 
and the putative non-structural protein.  These experiments have also tested and 
rejected some avenues of research. 
We now have a method for measuring the change in virus titer over the course 
of DXV infection.   Though qPCR has not been shown to be strictly quantitative in 
this case, it can however be used to measure relative levels of the virus in flies.  This 
technique has proven useful to other members of our laboratory who are investigating 
the effects that RNA interference (RNAi) and Drosophila innate immune system 
pathway mutants have on DXV growth.  They have been able to show variations in 
the rate of DXV proliferation in these mutants which correlate to increased 
susceptibility to DXV. 
The initial impetus for creating a recombinant form of DXV-NS was that there 
was no source of the natural protein.  Though existence of this non-structural protein 
was theorized and backed by circumstantial structural evidence, NS had never been 
detected in infected flies or cells, nor did it appear in in vitro transcription-translation 
systems with the viral genome.  We sought to circumvent this problem by producing 
two forms of epitope tagged NS protein.  One would come from a high-yield 
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expression vector suitable for purification which could serve as a detection control 
and aid in production of a DXV-NS antibody.  The other form would be capable of 
expression in a Drosophila cell line to study the effects of NS in the natural host of 
DXV.  Both forms would be created as His-tagged fusion proteins for dual 
identification and possibly for purification. 
The E. coli expression plasmid pET15b was initially selected for high-yield 
expression, but despite numerous attempts to troubleshoot this system and 
compensate for suspected plasmid instability, we were unable to produce DXV-NS.  
Problems also arose with the first Drosophila expression vector, the metal-inducible 
plasmid pMT.  The copper induction step added a variable which made it difficult to 
determine why the NS protein was failing to express at detectable levels.  With the 
lessons learned by the later success with pAc5.1-NS, it may now be worthwhile to go 
back and produce a stable transfection line with pMT-NS. 
The first system to successfully produce His-tagged DXV-NS was pAc5.1, a 
vector specifically designed for the constitutive expression of proteins of interest in 
the Schneider-2 Drosophila cell line.  Eliminating the induction step necessary for 
expression in pMT removed that variable from the system.  This construct was 
parlayed into a successful S2 stable line which, although it produced only a small 
amount of the recombinant protein, clearly produced a band at the correct position for 
a 27-kDa protein.   
The success with a Drosophila expression vector was soon followed by the 
creation of several isolates of recombinant baculovirus which expressed another form 
of the His-NS fusion protein.  The baculovirus version of NS was expressed at high 
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levels and was easily detectable in western blots with both anti-His and anti-NS 
antibodies. 
 The successful production of recombinant DXV-NS has direct applications to 
the ongoing study of the putative protein.  The anti-NS serum produced from an 
artificial linear peptide found in the NS sequence is an imperfect tool.  We have found 
it to be effective yet highly non-specific, but at the time, it was the only option for an 
antibody since we did not have a source of NS protein.  Now with His-tagged 
recombinant NS from the baculovirus expression isolates, we can affinity purify the 
anti-NS serum and create a more highly refined product.  If the linear peptide based 
NS antibody still proves inadequate following purification, the recombinant protein 
can also be used to inoculate and create a new antibody against the entire NS protein.   
 The problems encountered with the expression of recombinant forms of DXV-
NS can offer some insight into the role this putative protein could play.  The low 
levels of expression with the constitutively active vector could be indicative of some 
degree of toxicity to the cell.  If NS does exist in natural infection, this apparent 
toxicity may mean that it plays a role in the virus’ interaction with the host and that 
like the other small basic proteins in IPNV and IBDV, it may be pro-apoptotic in its 
natural form.  Perhaps DXV-NS is being produced at very low levels and/or only 
briefly during the course of infection.  Its highly basic nature makes it an ideal 
candidate for nucleic acid interactions as does the presence of the nuclear targeting 
signal.  It may also very well be the agent responsible for the anoxia sensitivity 
phenotype through an as yet unknown host interaction. 
 The position of the DXV-NS ORF, overlapping the polyprotein frame, is 
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unusual and would require a yet unknown scheme for translation.  The detection of -1 
frameshifting slippery sites upstream from NS could be the answer.  If NS is 
produced as a fusion with a portion of the polyprotein at a very low frameshift/read-
through ratio during translation, then the miniscule amount of this protein might elude 
detection and would run at a larger size.  It might even be a time-dependent event, 
only produced at a certain point in the DXV infection cycle.  We now have a 
construct which could be used to test the frameshifting theory.   
 We can test for -1 frameshifting events and quantify the frameshifting 
efficiency using the dual-luciferase reporter construct.  Evidence of an active -1 
frameshifting motif directly upstream from the NS ORF would give clues as to how 
NS may be expressed.  This would be a strong indicator that this protein does exist 
and is expressed as a fusion protein.  If the results are positive, this could also indicate 
that other Birnaviruses may have a similar overlapping reading frame expressing a 
non structural protein that has not been recognized because it lacks a start codon.  
If the -1 frameshift results are negative, it is still possible that the upstream 
sequence contains a previously undetected IRES motif.  This model can also be 
investigated by a modification the same dual-luciferase construct.  By inserting a stop 
codon after the rluc gene and splicing the putative IRES region between the two 
luciferase reporters, this creates a construct in which the second fluc signal would 






4.2  Future Study 
 
 The work outlined in this thesis has further developed our knowledge of the 
putative DXV non structural protein.  Viruses tend to be very economical; rarely do 
they carry material in their genome which does not serve a purpose.  The number of 
significant features related to NS which have now been identified begin to add up and 
make it increasingly unlikely that this is merely an artifact.  The tools developed 
through this thesis research open up a number of future opportunities, not just for the 
continued study of the NS putative protein but also to more generalized study of DXV, 
other Birnaviruses, and even host response to virus in D. melanogaster.   
 Our group has been developing a reverse genetics system for Drosophila-X 
Virus, a construct capable of producing virus from a cDNA clone.  This approach, 
while technically challenging, has been successfully accomplished with both IPNV 
and IBDV (Song, 2003).  From these reverse genetics constructs, we hope to produce 
viable DXV following transfection into host S2 cells and provide us with a tool to 
manipulate the DXV genome.  A genetic approach can be used to study the effects of 
mutations on the virus; in particular, a mutant that eliminates the NS ORF could 
inform us as to the function of NS in vivo.  If an NS-deleted mutant virus replicated 
slower, failed to proliferate, or produced a change in the anoxia sensitivity phenotype, 
this would be an excellent indicator that the non-structural protein does play a role in 
the DXV lifecycle.  In addition, we could see if defects in an NS deletion mutant 
could be rescued by growing the mutant in the S2 cell line expressing NS. 
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 There are three possible roles for the DXV-NS function which arise from what 
we know of NS sequence, its homology to IPNV and IBDV small basic proteins, and 
the Drosophila innate immune response to DXV.  First, the bipartite nuclear targeting 
signal found in the DXV-NS sequence could be an indication that the protein is 
localized in the nucleus of infected cells.  We now have tools to be able to investigate 
this.  The stable line expresses His-tagged NS in S2 cells and could be 
immunofluorescence stained with anti-His or anti-NS antibodies to determine 
whether the recombinant NS is localizing to the nucleus.  If a future “next generation” 
anti-NS antibody is produced using recombinant protein, this could also be used to 
look at localization in the course of DXV infection.  If NS is in the nucleus, this 
indicates that it may be involved in gene regulation. 
 The second possibility is that DXV-NS may be involved in apoptosis.  Its 
similarity to the small basic proteins of IPNV and IBDV lead to questions as to 
whether NS could also be implicated in apoptosis.  We might be able to test this 
model for NS function by looking for apoptotic effects in flies and cells.  
Programmed cell death is an important part of development, and apoptosis in tissues 
of Drosophila embryos is well studied (White et al., 1994).  With purified 
recombinant NS protein, we could inject embryos and look for changes in the normal 
pattern of cell death in the developing embryo.  If cell death effects are seen, then this 
may indicate that DXV-NS is linked to the apoptotic effects seen in IPNV and IBDV. 
 Finally, NS may suppress RNAi mechanisms.  We have found that Drosophila 
mutants affecting RNAi are more susceptible to DXV infection (Zambon, 
unpublished).  RNAi is thought to be the primary defense against dsRNA viruses (Li 
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et al., 2002)  Many viruses have evolved mechanisms to suppress RNAi and we can 
now test whether NS might play a role in DXV suppression of silencing.  We can also 
examine if RNAi mechanisms that normally function in S2 cells are perturbed in the 
stable line expressing DXV-NS and determine if NS affects the cells' use of RNAi to 
degrade double stranded RNA.  The use of the tools developed in this research may 
lead to discoveries reaching far beyond DXV and could give us clues into the innate 
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